Much more medicine for the oldest old: trends in UK electronic clinical records. by Melzer, D et al.
Age and Ageing 2015; 44: 46–53
doi: 10.1093/ageing/afu113
Published electronically 7 August 2014
© The Author 2014. Published by Oxford University Press on behalf of the British Geriatrics Society.
This is an Open Access article distributed under the terms of the Creative Commons Attribution
Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits
non-commercial re-use, distribution, and reproduction in any medium, provided the original work is
properly cited. For commercial re-use, please contact journals.permissions@oup.com
Much more medicine for the oldest old: trends
in UK electronic clinical records
DAVID MELZER1, BEHROOZ TAVAKOLY1, RACHEL E. WINDER2, JANE A. H. MASOLI1, WILLIAM E. HENLEY3,
ALESSANDRO BLE1, SUZANNE H. RICHARDS4
1Epidemiology and Public Health, University of Exeter Medical School, Barrack Road, Exeter EX2 5DW, UK
2Epidemiology and Public Health, University of Exeter Medical School, Smeall Building, St Luke’s Campus, Exeter EX1 2LU, UK
3Health Statistics Group, University of Exeter Medical School, St Luke’s Campus, Exeter EX1 2LU, UK
4Primary Care Research Group, University of Exeter Medical School, Smeall Building, St Luke’s Campus, Exeter EX1 2LU, UK
Address correspondence to: D. Melzer. Tel: +44(0)1392 406753. Email: d.melzer@exeter.ac.uk
Abstract
Background: the oldest old (85+) pose complex medical challenges. Both underdiagnosis and overdiagnosis are claimed in
this group.
Objective: to estimate diagnosis, prescribing and hospital admission prevalence from 2003/4 to 2011/12, to monitor trends
in medicalisation.
Design and setting: observational study of Clinical Practice Research Datalink (CPRD) electronic medical records from
general practice populations (eligible; n= 27,109) with oversampling of the oldest old.
Methods: we identiﬁed 18 common diseases and ﬁve geriatric syndromes (dizziness, incontinence, skin ulcers, falls and frac-
tures) from Read codes. We counted medications prescribed ≥1 time in all quarters of studied years.
Results: there were major increases in recorded prevalence of most conditions in the 85+ group, especially chronic kidney
disease (stages 3–5: prevalence <1% rising to 36.4%). The proportions of the 85+ group with ≥3 conditions rose from 32.2 to
55.1% (27.1 to 35.1% in the 65–84 year group). Geriatric syndrome trends were less marked. In the 85+ age group the propor-
tion receiving no chronically prescribed medications fell from 29.6 to 13.6%, while the proportion on ≥3 rose from 44.6 to
66.2%. The proportion of 85+ year olds with ≥1 hospital admissions per year rose from 27.6 to 35.4%.
Conclusions: there has been a dramatic increase in the medicalisation of the oldest old, evident in increased diagnosis (likely
partly due to better record keeping) but also increased prescribing and hospitalisation. Diagnostic trends especially for chronic
kidney disease may raise concerns about overdiagnosis. These ﬁndings provide new urgency to questions about the appropri-
ateness of multiple diagnostic labelling.
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Introduction
The numbers of ‘oldest old’ people (≥85 years) in the UK
will increase from 1.4 million in 2010 to 3.5 million by 2035
[1], with similar trends globally [2]. The oldest old people are
intensive users of acute hospitals, with rates of emergency
admission nearly 10 times higher than those aged 20–49
years [3]. However, there are few data on prevalence or
trends in diagnosed morbidity or treatment rates in the UK’s
oldest old.
Diagnosing and treating the oldest patients is challenging.
Distinguishing between incidental age-related changes, treat-
able disease and the process of dying can be a vexed issue
[4]. Comorbidity and frailty are common and the oldest old
people are often excluded from clinical trials [5] so the bene-
ﬁts and risks of diagnosis and intervention are often
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unknown. Evidence-based guidelines frequently prove
contradictory and unworkable in the oldest old [6]. Perhaps
because of these complexities, there have been claims of
both underdiagnosis and overdiagnosis in this group.
Underdiagnosis in general practice has been reported for
conditions including dementia [7], diabetes [8] and hyperten-
sion [9]. At the same time, overdiagnosis is causing major
concern especially for chronic kidney disease (CKD) [10],
chronic obstructive airways disease [11], certain cancers [12],
hypertension, osteoporosis, and early dementia [13, 14].
Overdiagnosis can lead to overintervention and questionable
beneﬁts for some patients [14], especially older patients.
Overdiagnosis often arises from imaging or laboratory ﬁnd-
ings of deviations from ‘normal’ levels [15], yet normal is
poorly deﬁned in the oldest old.
In England, the introduction of the Quality Outcomes
Framework (QOF) in 2004 ﬁnancially incentivised general
practitioners (GPs) to systematically electronically record the
presence of certain chronic diseases and the achievement of
associated quality indicators [16] that may have inﬂuenced
diagnostic rates. Recently announced changes to the GP con-
tract in England have highlighted the frail elderly, raising
further questions about appropriate diagnosis and treatment
in the oldest old.
We aimed to estimate trends in diagnosed disease and geri-
atric syndromes, polypharmacy and hospital admissions from
2003–04 to 2011–12, using the Clinical Practice Research
Datalink (CPRD). A major advantage is that CPRD includes
patients in residential and nursing homes, with essentially
complete inclusion of the frail and dependent, who are often
underrepresented in volunteer-based studies.
Methods
Cohort identification
The oldest old make up a small proportion of the overall
CPRD patient population. To maximise statistical power, we
selected a weighted sample with over-representation of the
oldest old (but weighted all analyses back to the UK popula-
tion structure 2011 to obtain representative estimates—see
statistical analysis). We included CPRD patients reaching age
100 years or more from 1 January 2002 to 31 December
2011, in the July 2012 CPRD data snapshot. Each centenar-
ian was matched (one to one for females, one to two for
males) to younger patients by practice, gender and calendar
year in the following age-groups: 65–74, 75–79, 80–84,
85–89, 90–94, 95 to 99 years. Additional data included Hospital
Episode Statistics (HES) and Ofﬁce for National Statistics
(ONS) mortality data for practices in the CPRD linkage
scheme.
Coding of disease
We studied 15 common conditions from studies of QOF dis-
eases by Salisbury et al. [17] and others [18], excluding learn-
ing disability and obesity. Any patient with a QOF diagnosis
(QOF business rules Version 18, October 2010) [19] and
(where appropriate) a drug Read code and appearing in the
records up to 15 years before the end of the analysis year
(e.g. for ﬁscal year 2003–04, from April 1989) was selected.
The Mental Health (major disorder) QOF group was the
only diagnosis potentially identiﬁed solely on the presence of
a drug code (lithium) or relevant diagnostic codes, and three
other conditions (asthma, epilepsy and hypothyroidism)
required accompanying drug codes as well as the relevant
diagnosis code. Patients who received relevant diagnoses
within our study periods (i.e. the previous 15 years for dis-
eases and 5 years for geriatric syndromes) were included in
estimates as having the condition, even if a subsequent
resolved code was also present (resolved codes were rare: e.g.
for hypertension only 1.2% of diagnosed cases also had a
resolved code in the whole database).
Osteoarthritis, osteoporosis (at the time not included as
QOF) and anaemia were added to this measure as common
disabling conditions of ageing.
Multi-morbidity was deﬁned as ≥3 conditions from our
15 QOF and three additional disorders (range 0–18). Five
geriatric syndromes were identiﬁed from Read codes for diz-
ziness (including vertigo and syncope), incontinence (urinary
and faecal), skin ulcers (including bed sores), falls and frac-
tures. Medical literature was examined to generate search
terms by two clinicians blinded to each other’s work, with a
third clinical reviewer arbitrating disagreements. Syndromes
were coded as present if relevant read or product coding
appeared in records up to 5 years before the end of the ana-
lysis year (e.g. for ﬁscal year 2003–04, from April 1999), to
exclude historical diagnoses with no recent mention.
Coding of polypharmacy
We included substances prescribed with predominantly sys-
temic effects (oral, sublingual, transdermal, subcutaneous,
intramuscular, intravenous, rectal), the vast majority of which
were oral (97.7%). A count of long-term (chronic) prescribed
drugs including drugs prescribed at least once per quarter for
all four-quarters of each studied year, to exclude short-term
prescriptions.
Statistics
We have estimated outcomes for ﬁscal years 2003–04 to
2011–12 for the 65–84 year olds and 85+ year olds separately,
to capture a period before and after the introduction of QOF.
For simplicity, we tabulate estimates in 2003–04, 2007–08
and 2011–12, with intermediate years presented in ﬁgures
for selected measures.
Our weighted database was built up by adding patients
who became centenarians in each year from 2002 to 2011,
with younger controls then added for each centenarian (see
Cohort Identiﬁcation above). For the 2003–04 estimates, the
subsample added by CPRD to our database in 2002 and
2003 only were used, to avoid including patients added in
subsequent years, which would have introduced survivor
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biases. We used the same approach for later periods (i.e.
patients added 2006 and 2007 only for 2007–08 estimates,
patients added 2010 and 2011 for 2011–12 estimates). Only
data for the periods during which patients were ‘actively’
registered with practices were included in analyses (i.e. we
used data from current registration date up to the date of last
data collection, transfer out of practice or death). Current
registration was ascertained on the mid-point of the studied
ﬁscal years (e.g. 30 September 2003 for 2003–04 estimates).
A small number of apparently ‘non-active’ patients (i.e. those
with no clinical or therapy records for the previous 3 years)
were also excluded. This rule excluded 28 patients in 2003–
04, 48 in 2007–08 and 71 patients in 2011–12, with 4,556,
5,574 and 6,223 eligible patients included, respectively. For
hospital admission statistics, 58% (338/578) of practices
were linked, covering England only. Data were analysed using
Stata 13.
To correct the oversampling of the oldest old, all esti-
mates were weighted back to the UK 2011 population struc-
ture (or the population of England 2011 for HES-England
analyses). Weights were computed from the ratio of the
number of people in the population of the UK in 2011
(ONS estimates) in each 5-year age group for men and
women separately divided by the numbers of CPRD patients
in each similar age–gender group in our analysis, for each
ﬁscal year separately. Weighted estimates were computed
using the STATA Survey commands which in this case
provide the estimates we would have got if our patient group
had the same age structure as the UK in 2011, thus removing
any bias from the over-representation of the very elderly or
changes in population structure.
We measured absolute percentage point differences in
prevalence between 2003–04 and 2011–12, as some trends
appear non-linear and modelled per year changes sometimes
produced misleading results.
Findings
From 2002–03 to 2011–12, 27,109 patients met eligibility cri-
teria and are included in graphs, with 16,353 included in the
three exemplar years for tables (2003–04, 2007–08 and 2011–
12). Supplementary data available in Age and Ageing online,
Table S1 describes the study sample (see Supplementary data
available in Age and Ageing online, Appendices S1–S4). In the
85+ group, 67% of the samples were women compared with
54% in the 65–84 age group (all estimates weighted to the UK
2011 population structure—see methods). Median lengths of
registration in the CPRD data for the 85+ group rose from
7.6 years in 2003–04 to 12.2 years in 2011–12, but were more
stable in the 65–84 group (12.5 and 12.7 years, respectively).
The prevalence of 18 common chronic diseases was esti-
mated for those aged 65–84 and 85+ years separately
(Table 1). In the oldest old, there were large increases in
prevalence for diabetes (8.3%; 95% CI: 7.1–9.5%), osteopor-
osis (9.8%; 95% CI: 8.3–11.3%), osteoarthritis (10.3%; 95%
CI: 8.0–12.6%) and hypertension (14.6%; 95% CI: 12.2–
17.0%). For CKD, the prevalence rose from <1–36.4%.
There were more modest changes in most of these condi-
tions in the 65–84 year olds. Only heart failure showed a fall
in prevalence in the 85+ group (absolute change of −3.3%;
95% CI: −5.0 to −1.6%), but there were modest reductions
for coronary heart disease and heart failure in the younger
group. Supplementary data available in Age and Ageing online,
Figure S1 (a–d) show prevalence trends for heart failure,
CKD (stages 3–5), diabetes and incontinence by age group.
Trends appear approximately linear except for CKD, which
shows a dramatic prevalence increase from 2005 to 2007.
The proportions of those aged 85+ years with three or
more conditions increased from 32.2 to 55.1% compared
with 27.1 to 35.1% in the younger group (Figure 1). Trends
in geriatric syndrome prevalence were similar, but less
marked (Supplementary data available in Age and Ageing
online, Table S2). Overall, the proportion of 85+ year olds
with two or more geriatric syndromes increased from 17.8 to
24.5%, while there was no signiﬁcant trend in the 65–84 age
group.
Trends in quantity of prescribing
The proportion of the oldest group chronically prescribed
three or more items rose from 44.6 to 66.2% (21.6 percent-
age point increase 95% CI: 18.4–24.8%) compared with a
change from 37.7 to 50.5% in the younger age group (12.8
percentage point increase, 95% CI: 9.5–16.1%)(Table 2). At
the same time the proportions of patients on no medication
fell, again more markedly in the oldest old.
Trends in hospital admission
Across the studied years, for the oldest old, the proportion
admitted at least once rose from 27.6 to 35.4% (difference
7.8%, 95% CI: 2.6–10.4%), but there was no signiﬁcant
change in the proportion of 65–84 year olds having one or
more hospital admission (Table 2). However, for emergency
admissions there were smaller trends for both age-groups.
Discussion
In this study of UK general practice, we found large-scale
increases in many diagnoses from 2003–04 to 2011–12,
especially in the oldest old. The proportion of the oldest old
on chronically prescribed medication or admitted to hospital
(in England) also rose markedly. Taken together the data in-
dicate a major shift towards more intensive medicalisation of
the oldest old.
Despite the many needs of the oldest old, there are few
studies with which we can compare our results. Local studies
using volunteer samples in Newcastle (aged exactly 85 at
baseline) [20] and the MRC CFAS study [21] provide some
overlaps. However, there are no comparable analyses of na-
tional trends in the oldest old, free of responder and loss to
follow-up biases, which can severely distort data on the frail
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Table 1. Prevalence of recorded diagnoses by age-group and fiscal year (weighted to UK population structure 2011), with absolute change in prevalence from 2003–04 to
2011–12
Disease 65–84 years old 85+ years old
2003–04 %
(95% CI)
2007–08 %
(95% CI)
2011–12 %
(95% CI)
Absolute difference %
(95% CI)
2003–04 %
(95% CI)
2007–08 %
(95% CI)
2011–12 %
(95% CI)
Absolute difference %
(95% CI)
Cardiovascular diseases
Hypertension 39.4 (36.5, 42.4) 43.6 (41.2, 46.1) 44.2 (41.9, 46.5) 4.8 (2.0, 7.6) 34.7 (31.6, 37.8) 45.7 (42.9, 48.5) 49.3 (47.0, 51.6) 14.6 (12.2, 17.0)
Arial fibrillation 6.2 (5.1, 7.6) 7.5 (6.4, 8.6) 7.0 (6.0, 8.0) 0.8 (−0.7, 2.3) 11.7 (10.0, 13.6) 15.2 (13.5, 17.1) 15.7 (14.0, 17.5) 4.0 (2.3, 5.7)
Coronary heart disease 18.8 (16.8, 21.0) 14.7 (13.2, 16.4) 15.0 (13.3, 16.8) −3.8 (−5.9, −1.7) 17.6 (15.4, 20.0) 21.9 (19.9, 24.1) 20.8 (19.1, 22.6) 3.2 (1.2, 5.2)
Heart failure 5.3 (4.3, 6.5) 3.7 (3.0, 4.5) 2.7 (2.1, 3.3) −2.6 (−3.8, −1.4) 12.2 (10.4, 14.2) 11.2 (9.7, 13.0) 8.9 (7.7, 10.3) −3.3 (−5.0, −1.6)
Stroke 8.9 (7.6, 10.5) 7.5 (6.3, 8.8) 7.5 (6.6, 8.6) −1.4 (−3, 0.2) 14.7 (12.8, 16.8) 16.3 (14.4, 18.4) 15.8 (14.3, 17.5) 1.1 (−0.8, 3)
Cancer 7.5 (6.2, 9.0) 8.5 (7.4, 9.8) 9.4 (8.1, 10.9) 1.9 (0.4, 3.4) 7.3 (6.0, 8.9) 10.2 (8.7, 11.9) 11.0 (9.6, 12.6) 3.7 (2.3, 5.1)
Chronic kidney disease
Stages 3–5 0.2 (0.1, 0.6) 14.5 (12.9, 16.2) 16.0 (14.4, 17.9) 15.8 (14.4, 17.2) 0.0 (0.0, 0.3) 27.4 (24.8, 30.1) 36.4 (33.9, 39.1) 36.4 (34.8, 38.0)
Respiratory
Asthma 8.3 (7.0, 9.9) 9.6 (8.3, 11.1) 10.5 (9.1, 12.2) 2.2 (0.6, 3.8) 6.0 (4.7, 7.6) 7.3 (6.1, 8.8) 7.8 (6.7, 9.2) 1.8 (0.6, 3)
COPD 5.9 (4.7, 7.4) 6.2 (5.2, 7.4) 7.8 (6.7, 9.1) 1.9 (0.5, 3.3) 4.7 (3.6, 6.2) 6.2 (5.1, 7.5) 6.7 (5.6, 7.9) 2.0 (0.9, 3.1)
Neuropsychiatric
Dementia 1.6 (1.1, 2.4) 1.8 (1.3, 2.4) 2.7 (2.1, 3.5) 1.1 (0.2, 2) 7.3 (6.0, 8.7) 10.3 (8.9, 12.0) 12.0 (10.6, 13.6) 4.7 (3.1, 6.3)
Depression 11.6 (10.0, 13.4) 11.8 (10.4, 13.2) 13.6 (12.2, 15.2) 2.0 (0.1, 3.9) 10.4 (8.6, 12.5) 12.0 (10.6, 13.7) 13.7 (12.1, 15.4) 3.3 (1.6, 5)
Mental health (psychoses, schizophrenia,
bipolar affective disease)
0.9 (0.4, 1.8) 1.4 (1.0, 2.0) 1.3 (0.9, 1.8) 0.4 (−0.2, 1) 1.0 (0.6, 1.7) 1.4 (1.0, 2.1) 1.7 (1.2, 2.4) 0.7 (0, 1.4)
Epilepsy 1.1 (0.6, 1.8) 1.8 (1.2, 2.6) 1.2 (0.8, 1.8) 0.1 (−0.5, 0.7) 1.1 (0.7, 2.0) 1.6 (1.1, 2.4) 0.9 (0.5, 1.5) −0.2 (−0.7, 0.3)
Endocrine
Diabetes 6.9 (5.8, 8.2) 12.1 (10.6, 13.8) 14.2 (12.5, 16.0) 7.3 (5.6, 9.0) 3.4 (2.5, 4.6) 8.9 (7.6, 10.4) 11.7 (10.3, 13.3) 8.3 (7.1, 9.5)
Hypothyroidism 6.8 (5.6, 8.3) 7.3 (6.3, 8.5) 8.3 (7.2, 9.6) 1.5 (−0.1, 3.1) 6.3 (5.1, 7.9) 9.1 (7.6, 10.8) 11.0 (9.7, 12.6) 4.7 (3.3, 6.1)
Additional common conditions
Anaemia 3.9 (3.1, 4.9) 6.2 (5.2, 7.4) 5.1 (4.1, 6.2) 1.2 (−0.1, 2.5) 8.7 (7.2, 10.5) 11.4 (9.8, 13.2) 11.9 (10.3, 13.5) 3.2 (1.7, 4.7)
Osteoarthritis 24.5 (22.2, 26.9) 27.7 (25.6, 29.8) 29.8 (27.6, 32.2) 5.3 (2.8, 7.8) 25.4 (22.8, 28.2) 33.1 (30.5, 35.8) 35.7 (33.4, 38.0) 10.3 (8.0, 12.6)
Osteoporosis 4.9 (3.9, 6.0) 7.4 (6.4, 8.6) 8.7 (7.5, 10.0) 3.8 (2.3, 5.3) 6.3 (5.1, 7.8) 9.8 (8.3, 11.5) 16.1 (14.3, 18.1) 9.8 (8.3, 11.3)
Multi-morbidity
≥3 of above conditions 27.1 (24.9, 29.4) 32.8 (30.5, 35.1) 35.1 (32.9, 37.4) 8.0 (5.5, 10.6) 32.2 (29.2, 35.3) 50.9 (47.9, 53.9) 55.1 (52.6, 57.5) 22.9 (20.4, 25.3)
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elderly [22, 23]. Studies of dementia and of diabetes in those
aged 65+ also in CPRD showed similar trends to those
reported here [24, 25]. The reported trend in heart failure is
supported by a recent English study ﬁnding of reduced rates
of hospital admissions and a fall in the practice-reported
prevalence of QOF diagnosed heart failure of 7.9% between
2006 and 2010 [26].
Studies of emergency admission trends [3] provide
broadly similar results at least for the earlier part of our
studied period, conﬁrming that rising emergency admission
rates result partly from increasing proportions of the 85+
age group being admitted to hospitals and not just increasing
re-admissions of the same patients.
Our largest reported diagnostic trend was for CKD,
which has been argued to be an example of overdiagnosis
[15]. While a small real increase in CKD may plausibly be
due to the diabetes epidemic, most of the diagnostic trend
appears to be due to the introduction of the QOF CKD
register in April 2006 and change in diagnostic approach to
one largely based on laboratory estimates of glomerular ﬁl-
tration rate (eGFR) evaluated against a standard that does
not account for advanced age. NHS clinical guidelines for
CKD were changed in 2008 to identify it earlier (by closer
review of those at risk of developing CKD and by monitor-
ing decline in eFGR) and to reduce numbers progressing to
end-stage renal failure [27]. In the older population, this
change aimed to detect CKD associated complications and
functional decline [10], although the beneﬁts of the resulting
labelling of over a third of the oldest old as having CKD are
unclear. One potential issue with our estimates is that the use
of the term ‘CKD’ was encouraged by the QOF incentive
scheme in 2006–07, which might have merely caused a sub-
stitution on diagnostic labels. We therefore undertook
further analyses of the prevalence of ‘chronic renal disease’,
‘chronic renal failure’, ‘end-stage renal failure’ and related
terms, which showed that the combined prevalence of diag-
noses broadly equivalent to CKD before 2005 were very low
(<1%). Further research has been advocated to measure the
Figure 1. Prevalence (weighted to UK population structure
2011) of number of chronic diseases (of 18 in Table 1) by age
group, from 2003–04 to 2011–12.
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impact of age and gender on outcomes stratiﬁed by level of
EGFR and the presence or absence of proteinuria [27].
It is tempting to attribute the diagnostic trends solely to the
QOF incentive payments to GPs, mostly introduced in 2004
and operationalised by 2006. While this may have contributed,
with the exception of CKD, most of the disease-speciﬁc trends
suggest that diagnostic rates have risen across the decade.
There was a reported modest improvement in recorded quality
of diabetes care in general practice for patients, but with no
obvious change in the upward trend for the diagnosis of dia-
betes [25]. Conditions outside of the QOF during the study
period (including osteoarthritis, osteoporosis and anaemia) also
show upward trends in prevalence. Changes to disease deﬁni-
tions can affect prevalence rates by, for example, labelling of
disease precursors, changing diagnostic thresholds or using dif-
ferent diagnostic methods [15].Trends may be due to improved
methods of valid diagnosis and treatment [28] for some condi-
tions. Finally, it is likely that a proportion of the diagnostic
trends documented are due to changes in GP coding of
disease that was previously not recorded or only in the free-text
material in their electronic records systems. Formal recording
of previously unformalised diagnoses may still represent an
important change in practice, especially for the disproportional-
ly affected 85+-year-old groups, as formal diagnosis may lead
to medico-legal, re-imbursement related and other responsibil-
ities to treat. Increased coding of disease with no other changes
in practice could not explain the increase in prescribing or hos-
pital use, nor the reduction in the prevalence of heart failure,
although the relative changes in prevalence for the former mea-
sures were higher: i.e. our results for the 85+ group suggest a
71% increase prevalence of multi-morbidity, a 48% increase in
the prevalence of receiving ≥3 medications and a 28% increase
in the proportion being admitted to hospital across the studied
period, The increased prevalence of multiple (recorded) diag-
noses also implies that risk and prognostic tools based on
earlier multi-morbidity counts may no longer be valid and may
need to be re-calibrated.
CPRD has many strengths in terms of population coverage
and inclusion of patients in nursing and residential homes.
However, analyses are dependent on the quality of the avail-
able coded material. Most chronic diagnoses have been found
to be well recorded although some were under-recorded, such
as musculoskeletal conditions and diabetes [29]. Also, we were
unable to quantify functional assessments, including, for
example, activity of daily living deﬁcits or degrees of cognitive
impairments, as these were very seldom recorded in the coded
data. We did not access free-text material from the CPRD
records as our analysis was focused on formal coded diagno-
ses. Free-text records can contain terms reﬂecting full diagno-
ses but also provisional or possible diagnoses or symptoms
for investigation. GP free text is only accessible through
CPRD searching of pre-speciﬁed terms (to preserve anonym-
ity). We considered that such searches for all 18 conditions
and 5 syndromes could not be accurately undertaken (certainly
not at reasonable cost). Our estimates should therefore be
seen as conservative and likely to represent some undercount-
ing of the real levels of morbidity.
A major limitation for the oldest old is that much of clin-
ical practice and prescribing has not been experimentally
evaluated, and older (especially frail) patients are frequently
excluded from trials [30]. Ultimately, it is therefore not easy
to say whether the trend towards more medicalisation of
the oldest old is likely to have net beneﬁcial or detrimental
effects. However, the trends presented will add impetus to
questions about the appropriateness of multiple diagnostic
labelling and the limited evidence of risks and beneﬁts of
multiple disease-speciﬁc interventions, especially for those
of advanced age and with complex needs. The reported
trends are likely to add to the debate about the balance
between a medical diagnosis led approach and geriatric
approaches aimed at maintaining or improving daily func-
tioning and quality of life and incorporating patients’
wishes [31].
Conclusion
Over the last decade, there has been a large-scale increase in
medicalisation of the oldest old, in terms of upward trends in
recorded diagnoses, chronic prescribing and hospital admis-
sion. Trends especially in recorded CKD may raise concerns
about overdiagnosis. These ﬁndings provide new urgency to
question the appropriateness of multiple diagnostic labelling
and the limited evidence of risks and beneﬁts of multiple
disease-speciﬁc interventions, especially for those of advanced
age and with complex needs.
Key points
• There were no national data on recent trends in diagnosis in
the oldest old (85+ years) or 65–84 year olds.
• Using CPRD and HES, we estimated diagnosis, prescribing
and hospital admission prevalence trends.
• Rises in disease prevalence, prescribing and hospital admis-
sion largest in oldest old.
• There has been a dramatic increase in the medicalisation of
the oldest old.
• Trends for CKD raise concerns about overdiagnosis.
Supplementary data
Supplementary data mentioned in the text is available to sub-
scribers in Age and Ageing online.
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Abstract
Background: animal studies suggest a neuroprotective role for leptin, but human studies have shown mixed results. We exam-
ined whether plasma leptin levels in individuals with mild cognitive impairment (MCI) were related to cognitive function at
baseline and whether higher leptin levels were associated with reduced risk of dementia.
Methods: we categorised 352 MCI participants into sex-speciﬁc tertiles based on log-transformed fasting plasma leptin levels.
In sex-stratiﬁed analyses, we investigated whether cognitive ability differed by leptin tertile. We also examined whether the risk
of dementia over a 3-year follow-up period differed by leptin level. Analyses controlled for numerous potential confounding
variables, including body mass index, hypertension and levels of blood insulin and C-reactive protein.
Results: baseline cognitive ability did not differ as a function of leptin level, nor were higher leptin levels associated with
reduced hazard of developing dementia. Controlling for related co-variates did not reveal any signiﬁcant associations between
leptin and dementia risk.
Conclusion: in this cohort of older adults with MCI, plasma leptin level was not associated with cognitive function at baseline,
nor did it predict risk of dementia. Other biological measures, such as volumetric MRI and cerebrospinal ﬂuid protein levels,
have demonstrated robust dementia prediction in this cohort. Thus, the current negative ﬁndings suggest that plasma leptin,
on its own, is unlikely to become a useful clinical biomarker for Alzheimer’s disease. Efforts to develop other blood-based
biomarkers are needed.
Keywords: Alzheimer’s disease, blood biomarker, MCI, dementia prediction, older people
Introduction
With the growing realisation that Alzheimer’s disease (AD)
pathology begins to accumulate years prior to the onset of
dementia, there is strong interest in developing reliable tests
to predict dementia risk. A blood-based test would be ideal
for reasons of cost, convenience and availability. One poten-
tial serum measure that has received much recent attention is
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